Diabetic cardiomyopathy (DCM) is a major complication of diabetes mellitus (DM) leading to increased morbidity and mortality. Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, plays a central role in DCM pathogenesis.
Data Synthesis:
This narrative review was conducted through a comprehensive literature search of major scientific databases, including PubMed, Scopus, and Web of Science, using keywords related to oxidative stress, inflammation, and diabetic cardiomyopathy. Peer-reviewed experimental and translational studies were critically analyzed and synthesized to elucidate key molecular mechanisms.
Conclusions:
This review highlights the molecular interplay between oxidative stress and inflammatory pathways—including Nrf2, NF-κB, and Sirt1 signaling—in promoting myocardial fibrosis, apoptosis, and dysfunction. Furthermore, therapeutic strategies targeting oxidative stress and inflammation, such as natural antioxidants and Nrf2 activators, show promise in mitigating DCM progression. Understanding these mechanisms provides new insights into potential interventions to prevent and treat diabetic heart disease.
SaeediPPetersohnISalpeaP, et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract2019; 157: 107843.
2.
ChoNHShawJEKarurangaS, et al.IDF Diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract2018; 138: 271–281.
3.
AssociationAD. Diagnosis and classification of diabetes mellitus. Diabetes Care2014; 37: S81–S90.
4.
EizirikDLPasqualiLCnopM. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol2020; 16: 349–362.
5.
KahnSECooperMEDel PratoS. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet2014; 383: 1068–1083.
6.
SuMTangTTangW, et al.Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review. Front Immunol2023; 14: 1243834.
7.
YaribeygiHKatsikiNBehnamB, et al.MicroRNAs and type 2 diabetes mellitus: molecular mechanisms and the effect of antidiabetic drug treatment. Metabolism2018; 87: 48–55.
8.
YaribeygiHFarrokhiFRButlerAE,et al.Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol2019; 234: 8152–8161.
9.
YaribeygiHButlerAEBarretoGE,et al.Antioxidative potential of antidiabetic agents: a possible protective mechanism against vascular complications in diabetic patients. J Cell Physiol2019; 234: 2436–2446.
10.
YaribeygiHMohammadiMTSahebkarA. Crocin potentiates antioxidant defense system and improves oxidative damage in liver tissue in diabetic rats. Biomed Pharmacother2018; 98: 333–337.
11.
YaribeygiHMohammadiMTSahebkarA. PPAR-α agonist improves hyperglycemia-induced oxidative stress in pancreatic cells by potentiating antioxidant defense system. Drug Res2018; 68: 355–360.
12.
HurrleSHsuWH. The etiology of oxidative stress in insulin resistance. Biomed J2017; 40: 257–262.
13.
HillMAYangYZhangL, et al.Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism2021; 119: 154766.
14.
DarenskayaMKolesnikovaLKolesnikovS. Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull Exp Biol Med2021; 171: 179–189.
15.
YaribeygiHLhafFSathyapalanT,et al.Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: implications for lowering tissue damage. Life Sci2019; 231: 116538.
16.
DinićSArambašić JovanovićJUskokovićA, et al.Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management. Front Endocrinol (Lausanne)2022; 13: 1006376.
17.
NakamuraKMiyoshiTYoshidaM, et al.Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci2022; 23: 3587.
18.
ZhuYZhangQWangY, et al.Identification of necroptosis and immune infiltration in heart failure through bioinformatics analysis. J Inflamm Res2025; 18: 2465–2481.
19.
DillmannWH. Diabetic cardiomyopathy: what is it and can it be fixed?Circ Res2019; 124: 1160–1162.
20.
RawshaniARawshaniAFranzénS, et al.Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med2017; 376: 1407–1418.
21.
LiWLiuXLiuZ, et al.The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review. Front Pharmacol2024; 15: 1416403.
22.
ChengXHuangJLiH, et al.Quercetin: a promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis. Phytomedicine2024; 126: 154887.
23.
ZhangZ-DTaoQQinZ, et al.Uptake and transport of naringenin and its antioxidant effects in human intestinal epithelial caco-2 cells. Front Nutr2022; 9: 894117.
24.
CalisZDasdelenDBaltaciAK,et al.Naringenin prevents inflammation, apoptosis, and DNA damage in potassium oxonate-induced hyperuricemia in rat liver tissue: roles of cytochrome C, NF-κB, caspase-3, and 8-hydroxydeoxyguanosine. Metab Syndr Relat Disord2022; 20: 473–479.
25.
DuYMaJFanY, et al.Naringenin: a promising therapeutic agent against organ fibrosis. Oxid Med Cell Longevity2021; 2021: 1210675.
26.
LiHLiuLCaoZ, et al.Naringenin ameliorates homocysteine induced endothelial damage via the AMPKα/Sirt1 pathway. J Adv Res2021; 34: 137–147.
27.
DayarathneLARanaweeraSSNatrajP, et al.The effects of naringenin and naringin on the glucose uptake and AMPK phosphorylation in high glucose treated HepG2 cells. J Vet Sci2021; 22: e92.
28.
YangYTrevethanMWangS,et al.Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: an update on bioavailability, pharmacokinetics, and mechanisms. J Nutr Biochem2022; 104: 108967.
29.
BellDS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease?Diabetes Care1995; 18: 708–714.
30.
RodriguesBMcNeillJH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res1992; 26: 913–922.
WeiXLiLZhaoG, et al.Hypertension and Alzheimer's disease: pathological interplay, comorbidity risks, and new strategies for synergistic management. Clin Exp Hypertens2025; 47: 2595154.
CaiLKangYJ. Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol2003; 3: 219–228.
38.
LiXXuZLiS,et al.Redox regulation of I to remodeling in diabetic rat heart. American Journal of Physiology-Heart and Circulatory Physiology2005; 288: H1417–H1H24.
39.
GrundySMBenjaminIJBurkeGL, et al.Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation1999; 100: 1134–1146.
40.
BrownleeM. Biochemistry and molecular cell biology of diabetic complications. Nature2001; 414: 813–820.
41.
WitztumJL. The role of oxidized LDL in the atherogenic process. J Atheroscler Thromb1994; 1: 71–75.
42.
van der WalACBeckerAE. Atherosclerotic plaque rupture–pathologic basis of plaque stability and instability. Cardiovasc Res1999; 41: 334–344.
43.
RaginoYIChernjavskiAPolonskayaYV, et al.Oxidation and endothelial dysfunction biomarkers of atherosclerotic plaque instability. Studies of the vascular wall and blood. Bull Exp Biol Med2012; 153: 331–335.
44.
CandidoRSrivastavaPCooperME,et al.Diabetes mellitus: a cardiovascular disease. Current Opinion in Investigational Drugs (London, England: 2000)2003; 4: 1088–1094.
45.
MilziABurgmaierMBurgmaierK, et al.Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study. Cardiovasc Diabetol2017; 16: –9.
46.
VirmaniRBurkeAPKolodgieF. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol2006; 22: 81B–84B.
47.
FordTJBerryCDe BruyneB, et al.Physiological predictors of acute coronary syndromes: emerging insights from the plaque to the vulnerable patient. JACC: Cardiovascular Interventions2017; 10: 2539–2547.
48.
DrakopoulouMToutouzasKStefanadiE, et al.Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis2009; 206: 335–339.
49.
SchnellORydénLStandlE, et al.Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol2016; 15: 1–12.
50.
BoothGLKapralMKFungK,et al.Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet2006; 368: 29–36.
51.
HussainSKhanAWAkhmedovA, et al.Hyperglycemia induces myocardial dysfunction via epigenetic regulation of JunD. Circ Res2020; 127: 1261–1273.
52.
HölscherMEBodeCBuggerH. Diabetic cardiomyopathy: does the type of diabetes matter?Int J Mol Sci2016; 17: 2136.
53.
ChenLLiuB. Relationships between stress granules, oxidative stress, and neurodegenerative diseases. Oxid Med Cell Longevity2017; 2017: 1809592.
54.
HalliwellB. Biochemistry of oxidative stress. Biochem Soc Trans2007; 35: 1147–1150.
55.
KaulNSiveski-IliskovicNHillM, et al.Free radicals and the heart. J Pharmacol Toxicol Methods1993; 30: 55–67.
56.
SingalPPetkauAGerrardJ, et al.Free radicals in health and disease. Mol Cell Biochem1988; 84: 121–122.
57.
JohansenJSHarrisAKRychlyDJ,et al.Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol2005; 4: 1–11.
CamiciGGSchiavoniMFranciaP, et al.Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci USA2007; 104: 5217–5222.
60.
PiconiLQuagliaroLCerielloA. Oxidative stress in diabetes. 2003.
61.
RoloAPPalmeiraCM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol2006; 212: 167–178.
62.
NishioYKanazawaANagaiY, et al.Regulation and role of the mitochondrial transcription factor in the diabetic rat heart. Mitochondrial Pathogenesis: From Genes and Apoptosis to Aging and Disease2004; 1011: 78–85.
63.
SheHZhengJZhaoG, et al.Arginase 1 drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia-induced vascular dysfunction. Signal Transduction and Targeted Therapy2025; 10: 67.
64.
AronsonD. Hyperglycemia and the pathobiology of diabetic complications. Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets2008; 45: 1–16.
65.
LiS-YYangXCeylan-IsikA, et al.Cardiac contractile dysfunction in lep/lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco (endo) plasmic reticulum ca 2+-ATPase and myosin heavy chain isozyme switch. Diabetologia2006; 49: 1434–1446.
66.
GuzikTJMussaSGastaldiD, et al.Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD (P) H oxidase and endothelial nitric oxide synthase. Circulation2002; 105: 1656–1662.
67.
DavidJARifkinWJRabbaniPS,et al.The Nrf2/Keap1/ARE pathway and oxidative stress as a therapeutic target in type II diabetes mellitus. J Diabetes Res2017; 2017: 4826724.
68.
LuoJYanDLiS, et al.Allopurinol reduces oxidative stress and activates Nrf2/p62 to attenuate diabetic cardiomyopathy in rats. J Cell Mol Med2020; 24: 1760–1773.
69.
ByrneNJParajuliNLevasseurJL, et al.Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. Basic to Translational Science2017; 2: 347–354.
70.
LiCZhangJXueM, et al.SGLT2 Inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol2019; 18: 1–13.
71.
JinQZhuQWangK, et al.Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NF-κB signalling pathway in diabetic cardiomyopathy rats. Mol Med Rep2021; 23: 1.
72.
WardynJDPonsfordAHSandersonCM. Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochem Soc Trans2015; 43: 621–626.
73.
Sathibabu UddandraoVBrahmanaiduPNivedhaP, et al.Beneficial role of some natural products to attenuate the diabetic cardiomyopathy through Nrf2 pathway in cell culture and animal models. Cardiovasc Toxicol2018; 18: 199–205.
74.
GuHLiuJJiangJ, et al.The role of Nrf2 signaling pathway in diabetic cardiomyopathy: from pathogenesis to traditional Chinese medicine interventions. Front Cardiovasc Med2025; 12: 2025.
75.
ZhaoCZhangYLiuH, et al.Fortunellin protects against high fructose-induced diabetic heart injury in mice by suppressing inflammation and oxidative stress via AMPK/nrf-2 pathway regulation. Biochem Biophys Res Commun2017; 490: 552–559.
76.
KosuruRKandulaVRaiU, et al.Pterostilbene decreases cardiac oxidative stress and inflammation via activation of AMPK/Nrf2/HO-1 pathway in fructose-fed diabetic rats. Cardiovasc Drugs Ther2018; 32: 147–163.
77.
LiXWuDTianY. Fibroblast growth factor 19 protects the heart from oxidative stress-induced diabetic cardiomyopathy via activation of AMPK/Nrf2/HO-1 pathway. Biochem Biophys Res Commun2018; 502: 62–68.
78.
LuYMengJZhuD, et al.Pedunculoside inhibits cardiomyocyte inflammatory biomarkers via Nrf2/HO-1 pathway in high glucose-induced H9c2 cells and diabetic cardiomyopathy model rats. Hum Exp Toxicol2025; 44: 09603271251322186.
79.
LiHShiYWangX, et al.Piceatannol alleviates inflammation and oxidative stress via modulation of the Nrf2/HO-1 and NF-κB pathways in diabetic cardiomyopathy. Chem-Biol Interact2019; 310: 108754.
80.
LorenzoOPicatosteBAres-CarrascoS, et al.Potential role of nuclear factor κB in diabetic cardiomyopathy. Mediat Inflamm2011; 2011: 652097.
81.
SakuraiHSuzukiSKawasakiN, et al.Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem2003; 278: 36916–36923.
82.
ChenY-MYuX-JLiuK-L, et al.Inhibition of hypothalamic inhibitor κb kinase β/nuclear transcription factor κB pathway attenuates metabolism and cardiac dysfunction in type 2 diabetic rats. Neuroendocrinology2020; 110: 899–913.
83.
KelleyNJeltemaDDuanY,et al.The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci2019; 20: 3328.
84.
WangYLiHLiY, et al.Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation. Phytother Res2019; 33: 2737–2748.
85.
ZhaolinZGuohuaLShiyuanW,et al.Role of pyroptosis in cardiovascular disease. Cell Prolif2019; 52: e12563.
86.
LuoBLiBWangW, et al.NLRP3 Gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PloS one2014; 9: e104771.
87.
Cho MJYoonS-JKimW, et al.Oxidative stress-mediated TXNIP loss causes RPE dysfunction. Exp Mol Med2019; 51: 1–13.
88.
WuNZhengBShaywitzA, et al.AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell2013; 49: 1167–1175.
89.
MungaiPTWaypaGBJairamanA, et al.Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol2011; 31: 3531–3545.
90.
YapMKKMisuanN. Exendin-4 from heloderma suspectum venom: from discovery to its latest application as type II diabetes combatant. Basic Clin Pharmacol Toxicol2019; 124: 513–527.
91.
WeiHBuRYangQ, et al.Exendin-4 protects against hyperglycemia-induced cardiomyocyte pyroptosis via the AMPK-TXNIP pathway. J Diabetes Res2019; 2019: 8905917.
92.
ZhangH-KYeYLiK-J, et al.Gypenosides prevent H 2 O 2-induced retinal ganglion cell apoptosis by concurrently suppressing the neuronal oxidative stress and inflammatory response. J Mol Neurosci2020; 70: 618–630.
93.
ZhangHChenXZongB, et al.Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP 3 inflammasome activation. J Cell Mol Med2018; 22: 4437–4448.
94.
LiLLuoWQianY, et al.Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses. Phytomedicine2019; 59: 152774.
95.
CaoRFangDWangJ, et al.ALDH2 Overexpression alleviates high glucose-induced cardiotoxicity by inhibiting NLRP3 inflammasome activation. J Diabetes Res2019; 2019: 4857921.
96.
LiuJ-jShentuL-mMaN, et al.Inhibition of NF-κB and wnt/β-catenin/GSK3β signaling pathways ameliorates cardiomyocyte hypertrophy and fibrosis in streptozotocin (STZ)-induced type 1 diabetic rats. Current Medical Science2020; 40: 35–47.
97.
ZouFWangLLiuH, et al.Sophocarpine suppresses NF-κB-mediated inflammation both in vitro and in vivo and inhibits diabetic cardiomyopathy. Front Pharmacol2019; 10: 1219.
98.
YoussefMEAbdelrazekHMMoustafaYM. Cardioprotective role of GTS-21 by attenuating the TLR4/NF-κB pathway in streptozotocin-induced diabetic cardiomyopathy in rats. Naunyn-Schmiedeberg's Arch Pharmacol2021; 394: 11–31.
99.
FuZMuiDZhuH,et al.Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models. Aging (Albany NY)2020; 12: 8640.
100.
KarbasforooshanHKarimiG. The role of SIRT1 in diabetic cardiomyopathy. Biomed Pharmacother2017; 90: 386–392.
101.
LiKZhaiMJiangL, et al.Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway. Oxid Med Cell Longevity2019; 2019: 6746907.
102.
YaoRCaoYWangC, et al.Taohuajing reduces oxidative stress and inflammation in diabetic cardiomyopathy through the sirtuin 1/nucleotide-binding oligomerization domain-like receptor protein 3 pathway. BMC Complementary Medicine and Therapies2021; 21: 1–13.
103.
SalminenAOjalaJHuuskonenJ, et al.Interaction of aging-associated signaling cascades: inhibition of NF-κB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci2008; 65: 1049–1058.
104.
XuCLiuC-HZhangD-L. MicroRNA-22 inhibition prevents doxorubicin-induced cardiotoxicity via upregulating SIRT1. Biochem Biophys Res Commun2020; 521: 485–491.
105.
ZhangBZhaiMLiB, et al.Honokiol ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. Oxid Med Cell Longevity2018; 2018: 3159801.
106.
WaldmanMCohenKYadinD, et al.Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’. Cardiovasc Diabetol2018; 17: 1–12.
107.
ZhangyinZYinfengJXuqingH. FRZB Attenuates ferroptosis and oxidative stress in diabetic cardiomyopathy by modulating the AMPK/PGC-1α signaling pathway: a novel cardioprotective mechanism. Discov Med2025; 37: 2978–2989.
108.
WaldmanMBellnerLVanellaL, et al.Epoxyeicosatrienoic acids regulate adipocyte differentiation of mouse 3T3 cells, via PGC-1α activation, which is required for HO-1 expression and increased mitochondrial function. Stem Cells Dev2016; 25: 1084–1094.
109.
YouleRJVan Der BliekAM. Mitochondrial fission, fusion, and stress. Science2012; 337: 1062–1065.
110.
DingMFengNTangD, et al.Melatonin prevents D rp1-mediated mitochondrial fission in diabetic hearts through SIRT 1-PGC 1α pathway. J Pineal Res2018; 65: e12491.
111.
WaldmanMAradMAbrahamNG,et al.The peroxisome proliferator-activated receptor-gamma coactivator-1α–heme oxygenase 1 axis, a powerful antioxidative pathway with potential to attenuate diabetic cardiomyopathy. Antioxid Redox Signaling2020; 32: 1273–1290.
112.
ZamoraMVillenaJA. Contribution of impaired insulin signaling to the pathogenesis of diabetic cardiomyopathy. Int J Mol Sci2019; 20: 2833.
113.
PanYJiNJiangL, et al.GPCRs identified on mitochondrial membranes: new therapeutic targets for diseases. J Pharm Anal2025; 15: 101178.
BalakumarPSambathkumarRMahadevanN, et al.A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities: mechanisms and therapeutic implications. Pharmacol Res2019; 146: 104314.
116.
ClimentMViggianiGChenY-W, et al.MicroRNA and ROS crosstalk in cardiac and pulmonary diseases. Int J Mol Sci2020; 21: 4370.
117.
KaulNSiveski-IliskovicNThomasTP, et al.Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition (Burbank, Los Angeles County, Calif)1995; 11: 551–554.
118.
KaulNSiveski-IliskovicNHillM, et al.Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem1996; 160: 283–288.
119.
TurdiSLiQLopezFL,et al.Catalase alleviates cardiomyocyte dysfunction in diabetes: role of akt, forkhead transcriptional factor and silent information regulator 2. Life Sci2007; 81: 895–905.
120.
HeXChenMGMaQ. Activation of Nrf2 in defense against cadmium-induced oxidative stress. Chem Res Toxicol2008; 21: 1375–1383.
121.
LiinamaaMJSavolainenMJ. High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins. Ann Med2008; 40: 209–214.
122.
EurichDTMajumdarSRTsuyukiRT,et al.Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care2004; 27: 1330–1334.
123.
SonSM. Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. Diabetes Res Clin Pract2007; 77: S65–S70.
124.
HamblinMFriedmanDBHillS, et al.Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol2007; 42: 884–895.
125.
ShirpoorASalamiSKhadem-AnsariMH, et al.Cardioprotective effect of vitamin E: rescues of diabetes-induced cardiac malfunction, oxidative stress, and apoptosis in rat. J Diabetes Complicat2009; 23: 310–316.
126.
KuhadAChopraK. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci2009; 84: 296–301.
127.
BowieAO’NeillLA. Oxidative stress and nuclear factor-κB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol2000; 59: 13–23.
128.
PacherPSzaboC. Role of the peroxynitrite-poly (ADP-ribose) polymerase pathway in human disease. Am J Pathol2008; 173: 2–13.
129.
Jandeleit-DahmKALassilaMAllenTJ. Advanced glycation End products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci2005; 1043: 759–766.
130.
TangMZhongMShangY, et al.Differential regulation of collagen types I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway. Cell Mol Life Sci2008; 65: 2924–2932.
131.
FengBChenSChiuJ, et al.Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. American Journal of Physiology-Endocrinology and Metabolism2008; 294: E1119–E1E26.
132.
MaritimASandersRWatkins IiiJ. Effects of α-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats. J Nutr Biochem2003; 14: 288–294.
133.
IaccarinoGCiccarelliMSorrientoD, et al.Ischemic neoangiogenesis enhanced by β2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res2005; 97: 1182–1189.
134.
OkutanHOzcelikNYilmazHR,et al.Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin Biochem2005; 38: 191–196.
135.
ZhouGLiXHeinDW, et al.Metallothionein suppresses angiotensin II–induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol2008; 52: 655–666.
136.
JiaJ-HChenK-PChenS-X, et al.Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol2008; 63: 757–762.
137.
MiWXiaYBianY. The influence of ICAM1 rs5498 on diabetes mellitus risk: evidence from a meta-analysis. Inflammation Res2019; 68: 275–284.
138.
Van LinthoutSSpillmannFRiadA, et al.Human apolipoprotein AI gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation2008; 117: 1563–1573.
139.
MilneBSutakMCahillC,et al.Low doses of α2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br J Pharmacol2008; 155: 1264–1278.
140.
ManfulCFFordjourEIkumoineinE, et al.Therapeutic strategies targeting oxidative stress and inflammation: a narrative review. BioChem2025; 5: 35.
141.
MercurioVCuomoACadeddu DessalviC, et al.Redox imbalances in ageing and metabolic alterations: implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC). Antioxidants2020; 9: 41.
142.
FanHWangHLianZ, et al.Dynamic Interactions Between Hemispheres Reveal a Compensatory Pathway for Motor Recovery in Moderate-to-Severe Subcortical Stroke. J Stroke2026; 28: 97–114.
143.
WuXZhangKKuangN, et al.Developing brain asymmetry shapes cognitive and psychiatric outcomes in adolescence. Nat Commun2025; 16: 4480.
144.
KuangNLiuZYuG, et al.Neurodevelopmental risk and adaptation as a model for comorbidity among internalizing and externalizing disorders: genomics and cell-specific expression enriched morphometric study. BMC Med2023; 21: 91.
145.
MünzelTDaiberA. Environmental stressors and their impact on health and disease with focus on oxidative stress. Antioxid Redox Signaling2017; 28: 735–740.
